Aulia Fikri Hidayat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aulia Fikri Hidayat has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Taufik Muhammad Fakih
Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jalan Raya Bandung-Sumedang KM 21, Jatinangor 45363, Indonesia
3 shared publications - Dwi Syah Fitra Ramadhan
Poltekkes Kemenkes Makassar
2 shared publications A. M. Devi
Department of Pharmacy, Universitas Islam Bandung, Jalan Ranggagading No. 8, Bandung, Indonesia
1 shared publication- Aden Dhana Rizkita
Department of Pharmacy, Sekolah Tinggi Ilmu Kesehatan (STIKES) Bogor Husada
1 shared publication Ahmed Fouad Abdelwahab Mohammed
Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt
1 shared publication- Farendina Suarantika
Universitas Islam Bandung, Bandung, Indonesia
1 shared publication
Latest Publications
- Open Access
- 18 July 2025
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 53 (1) , 304-325
Virtual screening, molecular docking, and molecular dynamics simulation reveal new insights into RNA polymerase inhibition for anti-tuberculosis drug discovery
This study aims to identify potential RNA polymerase (RNAP) inhibitors using a comprehensive computational approach, addressing the challenges in drug discovery related to stability, affinity, and accurate binding predictions. The research workflow involved virtual screening to narrow down candidate compounds, molecular docking to predict optimal binding poses, molecular dynamics (MD) simulations to evaluate interaction stability over time, and MM-PBSA analysis to calculate binding energies. These steps ensured that only compounds with strong and stable binding profiles were selected for further evaluation. The selected compounds, ZINC001286671821, ZINC000253654686, and ZINC000252693842, demonstrated varying degrees of stability and affinity. MM-PBSA analysis revealed that ZINC000252693842 had the most favourable binding energy at -106.097 ± 24.664 kJ/mol, followed by ZINC001286671821 at -89.201 ± 22.647 kJ/mol, and ZINC000253654686 at -43.832 ± 23.748 kJ/mol. Van der Waals forces were the main contributors to stability, with values of -221.032 ± 27.721 kJ/mol, -187.136 ± 23.796 kJ/mol, and -157.232 ± 19.676 kJ/mol, respectively. These findings confirm the strong binding potential of ZINC000252693842 as an RNAP inhibitor. This study highlights the effectiveness of combining virtual screening, molecular docking, MD simulations, and MM-PBSA analysis in identifying promising RNAP inhibitors. The results establish a strong foundation for further experimental validation, advancing the development of effective therapeutic agents targeting RNA polymerase.
- 18 July 2025
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 53 (1) , 304-325
Open AccessVirtual screening, molecular docking, and molecular dynamics simulation reveal new insights into RNA polymerase inhibition for anti-tuberculosis drug discovery
This study aims to identify potential RNA polymerase (RNAP) inhibitors using a comprehensive computational approach, addressing the challenges in drug discovery related to stability, affinity, and accurate binding predictions. The research workflow involved virtual screening to narrow down candidate compounds, molecular docking to predict optimal binding poses, molecular dynamics (MD) simulations to evaluate interaction stability over time, and MM-PBSA analysis to calculate binding energies. These steps ensured that only compounds with strong and stable binding profiles were selected for further evaluation. The selected compounds, ZINC001286671821, ZINC000253654686, and ZINC000252693842, demonstrated varying degrees of stability and affinity. MM-PBSA analysis revealed that ZINC000252693842 had the most favourable binding energy at -106.097 ± 24.664 kJ/mol, followed by ZINC001286671821 at -89.201 ± 22.647 kJ/mol, and ZINC000253654686 at -43.832 ± 23.748 kJ/mol. Van der Waals forces were the main contributors to stability, with values of -221.032 ± 27.721 kJ/mol, -187.136 ± 23.796 kJ/mol, and -157.232 ± 19.676 kJ/mol, respectively. These findings confirm the strong binding potential of ZINC000252693842 as an RNAP inhibitor. This study highlights the effectiveness of combining virtual screening, molecular docking, MD simulations, and MM-PBSA analysis in identifying promising RNAP inhibitors. The results establish a strong foundation for further experimental validation, advancing the development of effective therapeutic agents targeting RNA polymerase.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8611-8651
A Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug Delivery: From Framework to Formulation
Oral administration is the most preferred route for drug delivery due to its convenience, non-invasiveness, and patient compliance. However, it is challenged by gastrointestinal barriers, enzymatic degradation, and first-pass metabolism, which reduce drug bioavailability. Lipid nanoparticles (LNPs), including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), offer a promising strategy to overcome these limitations by enhancing drug stability, permeability, and absorption. The Quality by Design (QbD) framework provides a systematic approach for LNP development to ensure consistent product quality. By promoting process understanding and control, QbD not only supports scientific formulation development but also enhances industrial scalability by reducing the experimental workload, shortening the development time, and lowering the production costs. This review highlights key QbD elements such as the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), critical process parameters (CPPs), and design of experiments (DoE) and their roles in guiding formulation and process optimization. The effects of various CMAs and CPPs on the CQAs such as particle size, polydispersity index, encapsulation efficiency, zeta potential, and drug release are discussed. Furthermore, the in vitro, in vivo, and ex vivo performances of optimized LNPs were explored in detail. Overall, QbD offers a robust platform for the rational design and scalable production of high-quality lipid-based drug delivery systems for oral administration.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8611-8651
Top Cited PapersOpen AccessA Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug Delivery: From Framework to Formulation
Oral administration is the most preferred route for drug delivery due to its convenience, non-invasiveness, and patient compliance. However, it is challenged by gastrointestinal barriers, enzymatic degradation, and first-pass metabolism, which reduce drug bioavailability. Lipid nanoparticles (LNPs), including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), offer a promising strategy to overcome these limitations by enhancing drug stability, permeability, and absorption. The Quality by Design (QbD) framework provides a systematic approach for LNP development to ensure consistent product quality. By promoting process understanding and control, QbD not only supports scientific formulation development but also enhances industrial scalability by reducing the experimental workload, shortening the development time, and lowering the production costs. This review highlights key QbD elements such as the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), critical process parameters (CPPs), and design of experiments (DoE) and their roles in guiding formulation and process optimization. The effects of various CMAs and CPPs on the CQAs such as particle size, polydispersity index, encapsulation efficiency, zeta potential, and drug release are discussed. Furthermore, the in vitro, in vivo, and ex vivo performances of optimized LNPs were explored in detail. Overall, QbD offers a robust platform for the rational design and scalable production of high-quality lipid-based drug delivery systems for oral administration.
- Open Access
- 27 June 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-14
Improving the solubility of remdesivir–cyclodextrin encapsulations in water-saturated 1-octanol solution: A molecular dynamics simulation study
Remdesivir was selected as a treatment for viral infections due to its efficacy as an antiviral agent against various RNA viruses such as Ebola and coronaviruses. The drug exerts its benefits during the later stages of viral infection, particularly post-fusion, endocytosis, translation, and proteolysis within host cells. It integrates into emerging viral RNA chains, disrupting transcription and ultimately inhibiting replication. However, its low water solubility poses limitations for clinical development. To enhance its solubility, current efforts focus on creating drug inclusion complexes using cyclodextrin derivatives. In this study, in silico techniques, including molecular docking and molecular dynamics simulations, were employed to investigate the molecular mechanisms and stability of remdesivir encapsulation using cyclodextrin derivatives. Various cyclodextrins were utilized, including beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (HPBCD), and sulfobutylether-beta-cyclodextrin (SBCD), docked against remdesivir. Molecular dynamics simulations were conducted in a water-saturated 1-octanol environment, a biphasic solvent system frequently used to mimic biological membrane conditions and assess solubility and partitioning behavior. Molecular docking results indicated that the complexes of remdesivir with HPBCD and SBCD exhibited the lowest binding energies of −10.69 kcal/mol and −8.34 kcal/mol, respectively. Furthermore, molecular dynamics simulations over 100 ns showed that these complexes maintained good stability. Analysis of molecular motion, RMSD, RDF, Rg, and SASA revealed increased water solubility and stability of the complexes. This evidence suggests that encapsulating remdesivir with HPBCD and SBCD can enhance its solubility.
- 27 June 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-14
Open AccessImproving the solubility of remdesivir–cyclodextrin encapsulations in water-saturated 1-octanol solution: A molecular dynamics simulation study
Remdesivir was selected as a treatment for viral infections due to its efficacy as an antiviral agent against various RNA viruses such as Ebola and coronaviruses. The drug exerts its benefits during the later stages of viral infection, particularly post-fusion, endocytosis, translation, and proteolysis within host cells. It integrates into emerging viral RNA chains, disrupting transcription and ultimately inhibiting replication. However, its low water solubility poses limitations for clinical development. To enhance its solubility, current efforts focus on creating drug inclusion complexes using cyclodextrin derivatives. In this study, in silico techniques, including molecular docking and molecular dynamics simulations, were employed to investigate the molecular mechanisms and stability of remdesivir encapsulation using cyclodextrin derivatives. Various cyclodextrins were utilized, including beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin (HPBCD), and sulfobutylether-beta-cyclodextrin (SBCD), docked against remdesivir. Molecular dynamics simulations were conducted in a water-saturated 1-octanol environment, a biphasic solvent system frequently used to mimic biological membrane conditions and assess solubility and partitioning behavior. Molecular docking results indicated that the complexes of remdesivir with HPBCD and SBCD exhibited the lowest binding energies of −10.69 kcal/mol and −8.34 kcal/mol, respectively. Furthermore, molecular dynamics simulations over 100 ns showed that these complexes maintained good stability. Analysis of molecular motion, RMSD, RDF, Rg, and SASA revealed increased water solubility and stability of the complexes. This evidence suggests that encapsulating remdesivir with HPBCD and SBCD can enhance its solubility.
- 26 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (14) , 7673-7684
Predicting anti-COVID-19 potential: in silico analysis of Mauritine compound from Ziziphus-spina christi as a promising papain-like protease (PLpro) inhibitor
The COVID-19 pandemic caused by the SARS-CoV-2 virus, recognized by the World Health Organization (WHO), has led to 164,523,894 confirmed cases and 3,412,032 deaths globally as of May 20, 2021. SARS-CoV-2 encodes crucial proteases for its replication cycle, including the papain-like protease (PLpro), presenting a potential target for developing COVID-19 treatments. Mauritine, a cyclopeptide alkaloid found in the Ziziphus-spina christi plant, exhibits antiviral properties and was investigated for its affinity and toxicity towards PLpro using molecular docking through MGLTools 1.5.6 with Autodock Tools 4.2. Preceding this, toxicity and ADME prediction were performed via Toxtree 3.1.0 software and SwissADME servers. Results from molecular docking revealed free binding energy values of -8.58; -7.73; -8.36; -6.07; -6.67; -7.83; -7.67; -7.40; and -6.87 Kcal/mol for Mauritine-A, Mauritine-B, Mauritine-C, Mauritine-D, Mauritine-F, Mauritine-H, Mauritine-J, Mauritine-L, and Mauritine-M, respectively. Correspondingly, inhibition constants were 0.51724; 2.14; 0.7398; 35.43; 12.95; 1.83; 2.38; 3.80; and 9.17 µM, respectively. Interactions observed included hydrogen bonds, hydrophobic interactions, and electrostatic interactions between the Mauritine compounds and the receptor. Mauritine-A and Mauritine-C emerged as a promising anti-COVID-19 candidate due to its superior affinity compared to other derivatives, as indicated by research findings. Interestingly, Mauritine-A and Mauritine-C exhibits notable stability as depicted by the RMSD and RMSF graphs, along with a considerable MM-PBSA binding free energy value of -162.431 and -137.500 kJ/mol, respectively.Communicated by Ramaswamy H. Sarma.
- 26 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (14) , 7673-7684
Predicting anti-COVID-19 potential: in silico analysis of Mauritine compound from Ziziphus-spina christi as a promising papain-like protease (PLpro) inhibitor
The COVID-19 pandemic caused by the SARS-CoV-2 virus, recognized by the World Health Organization (WHO), has led to 164,523,894 confirmed cases and 3,412,032 deaths globally as of May 20, 2021. SARS-CoV-2 encodes crucial proteases for its replication cycle, including the papain-like protease (PLpro), presenting a potential target for developing COVID-19 treatments. Mauritine, a cyclopeptide alkaloid found in the Ziziphus-spina christi plant, exhibits antiviral properties and was investigated for its affinity and toxicity towards PLpro using molecular docking through MGLTools 1.5.6 with Autodock Tools 4.2. Preceding this, toxicity and ADME prediction were performed via Toxtree 3.1.0 software and SwissADME servers. Results from molecular docking revealed free binding energy values of -8.58; -7.73; -8.36; -6.07; -6.67; -7.83; -7.67; -7.40; and -6.87 Kcal/mol for Mauritine-A, Mauritine-B, Mauritine-C, Mauritine-D, Mauritine-F, Mauritine-H, Mauritine-J, Mauritine-L, and Mauritine-M, respectively. Correspondingly, inhibition constants were 0.51724; 2.14; 0.7398; 35.43; 12.95; 1.83; 2.38; 3.80; and 9.17 µM, respectively. Interactions observed included hydrogen bonds, hydrophobic interactions, and electrostatic interactions between the Mauritine compounds and the receptor. Mauritine-A and Mauritine-C emerged as a promising anti-COVID-19 candidate due to its superior affinity compared to other derivatives, as indicated by research findings. Interestingly, Mauritine-A and Mauritine-C exhibits notable stability as depicted by the RMSD and RMSF graphs, along with a considerable MM-PBSA binding free energy value of -162.431 and -137.500 kJ/mol, respectively.Communicated by Ramaswamy H. Sarma.
- Open Access
- 27 December 2022
- Published by Knowledge E DMCC in KnE Life Sciences
- p. 282–289
Oxidative Stability of Nano-Encapsulated Candlenut Oil
Candlenut has a lot of potential pharmacological benefits including in hair care, in treating skin problems such as psoriasis, and in its use as an emollient. However, the high unsaturated fatty acid content of candlenut oil causes it to be easily degraded by oxidation due to exposure to air, light, and humidity. Nanoencapsulations were found to be an alternative in protecting the materials from degradation. The purpose of this study was to investigate the effect of polymer-based nanoencapsulations on the oxidative stability of candlenut oil. Polyvinyl alcohol (PVA) was used as a polymer wall material. A lower peroxide value indicates better oil stability against oxidation. Results showed that nano-encapsulated candlenut oil has a significantly lower average peroxide value of 0.41 meq/100g over 35 days storage time, compared to 3.8 meq/100g in pure candlenut oil. Furthermore, based on its physical characterization, it was found that the reduction of particle size with the optimal size of 172±12 nm was achieved by increasing the amount of PVA. A well-chosen and well-calculated amount of polymer material, therefore, plays an important role to obtain optimal nano-encapsulated candlenut oil. Keywords: nanoencapsulation, candlenut oil, oxidative stability, polymeric materials
- 27 December 2022
- Published by Knowledge E DMCC in KnE Life Sciences
- p. 282–289
Open AccessOxidative Stability of Nano-Encapsulated Candlenut Oil
Candlenut has a lot of potential pharmacological benefits including in hair care, in treating skin problems such as psoriasis, and in its use as an emollient. However, the high unsaturated fatty acid content of candlenut oil causes it to be easily degraded by oxidation due to exposure to air, light, and humidity. Nanoencapsulations were found to be an alternative in protecting the materials from degradation. The purpose of this study was to investigate the effect of polymer-based nanoencapsulations on the oxidative stability of candlenut oil. Polyvinyl alcohol (PVA) was used as a polymer wall material. A lower peroxide value indicates better oil stability against oxidation. Results showed that nano-encapsulated candlenut oil has a significantly lower average peroxide value of 0.41 meq/100g over 35 days storage time, compared to 3.8 meq/100g in pure candlenut oil. Furthermore, based on its physical characterization, it was found that the reduction of particle size with the optimal size of 172±12 nm was achieved by increasing the amount of PVA. A well-chosen and well-calculated amount of polymer material, therefore, plays an important role to obtain optimal nano-encapsulated candlenut oil. Keywords: nanoencapsulation, candlenut oil, oxidative stability, polymeric materials
- Open Access
- 1 November 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1375 (1) , 012078
Effect of solid lipid nanoparticles system on the stability of Green Tea leaves (Camellia sinensis L. Kuntze) extract as sunscreen
Green tea (Camellia sinensisL.) is known to have activity as antioxidant and sunscreen due to its catechin compound. The major catechin-derived compound is epigallocatechin gallate (EGCG). However, EGCG in green tea leaves is unstable due to its rapid degradation and large molecular mass of 458 daltons, making it difficult to penetrate the skin. The purpose of this research is to formulate solid lipid nanoparticles (SLN) of green tea leaves ethanol extract using high speed homogenization and sonication method, as well as to evaluate SLN ability in improving extract stability as sunscreen using UV-Vis spectrophotometry. SLN formula contained 0,1% green tea leaves ethanol extract, and the most optimal formula was composed of 4% lipid (Precirol ATO 5:Gelucire 44/14) 4:1 and 1% Kolliphor P188 as surfactant. Characterization results showed particle size of 286.7 nm, polydispersity index 0.296, and zeta potential -3.7 mV. Photostability test using 120-minutes irradiation showed decrease in percentage of DPPH free radicals damping at 5.34% extract and 1.77% SLN for UVA, and 7.7% extract and 2.34% SLN for UVB.
- 1 November 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1375 (1) , 012078
Open AccessEffect of solid lipid nanoparticles system on the stability of Green Tea leaves (Camellia sinensis L. Kuntze) extract as sunscreen
Green tea (Camellia sinensisL.) is known to have activity as antioxidant and sunscreen due to its catechin compound. The major catechin-derived compound is epigallocatechin gallate (EGCG). However, EGCG in green tea leaves is unstable due to its rapid degradation and large molecular mass of 458 daltons, making it difficult to penetrate the skin. The purpose of this research is to formulate solid lipid nanoparticles (SLN) of green tea leaves ethanol extract using high speed homogenization and sonication method, as well as to evaluate SLN ability in improving extract stability as sunscreen using UV-Vis spectrophotometry. SLN formula contained 0,1% green tea leaves ethanol extract, and the most optimal formula was composed of 4% lipid (Precirol ATO 5:Gelucire 44/14) 4:1 and 1% Kolliphor P188 as surfactant. Characterization results showed particle size of 286.7 nm, polydispersity index 0.296, and zeta potential -3.7 mV. Photostability test using 120-minutes irradiation showed decrease in percentage of DPPH free radicals damping at 5.34% extract and 1.77% SLN for UVA, and 7.7% extract and 2.34% SLN for UVB.